A groundbreaking study reveals a strong demand for new male contraceptives worldwide. Researchers surveyed over 18,000 men and 9,000 women across seven countries, uncovering widespread interest in male birth control options. The findings suggest male contraceptives could transform family planning and promote gender equity in reproductive health.
Key findings on male contraceptive demand
The study, led by an international team of scientists, was published in Andrology in October 2024. It found that 61% of men were interested in trying novel male contraceptives within the first year of availability. Interest varied by region, peaking at 76% in Nigeria and Bangladesh. In the United States, demand increased from 39% to 49% after the Supreme Court’s Dobbs decision restricted abortion access.
Women also showed confidence in their partners’ willingness and ability to use male contraceptives effectively. Over 85% of women in Bangladesh and Vietnam expressed trust in their partners to manage contraception responsibly.
Addressing gaps in male contraceptive research
Despite strong interest, most research on male contraceptives focuses on wealthier countries and outdated data. Many studies assess hypothetical demand without examining preferences for specific product features. This gap limits commercial confidence and investment, slowing development and leaving governments and private foundations to fund research.
With over 23 male contraceptives in development, including several in clinical trials, more research is needed—especially in low- and middle-income countries (LMICs) where contraceptive needs are highest. This study helps fill that gap by measuring interest in male contraceptives and preferences for their features across seven regions, including six LMICs and the U.S. These countries represent over half the unmet contraceptive need identified by FP2030, a global family planning coalition.
Why the demand for male contraceptives is rising
Nearly half of all pregnancies in low- and middle-income countries are unintended, highlighting an urgent need for more contraceptive options. The study’s findings emphasize that male contraceptives could fill this gap. With women expressing trust in their partners, the data supports a shift toward shared responsibility in preventing pregnancies.
In the U.S., the Dobbs decision added urgency to this shift. As abortion access narrowed, interest in male contraceptives grew. This trend highlights the importance of expanding options for men to actively participate in family planning.
Current progress in male contraceptive development
Several male contraceptives are now in development. Hormonal options funded by the U.S. National Institutes of Health are advancing through clinical trials. Non-hormonal alternatives, which appeal to more men, remain underfunded but show promise.
For example, YourChoice Therapeutics is testing YCT-529, a reversible, non-hormonal pill that prevents sperm production. In animal trials, it was 99% effective and reversible within weeks. Such products align with the preferences identified in the study, which favor oral and non-invasive methods.
Other innovations include long-acting injectable gels like Adam and Plan A (using the Vasalgel polymer), which block sperm in the vas deferens.
A call for investment in male contraceptives
The study underscores the urgent need for funding and policy support. With 23 male contraceptive products in development, the demand for male contraceptives offers a clear market opportunity. Researchers and advocates emphasize that these products can improve reproductive health and reduce unintended pregnancies.
Organizations like the Male Contraceptive Initiative are leading efforts to expand choices. Their focus on non-hormonal solutions ensures men have options that fit their lifestyles and preferences. Continued investment could accelerate progress and bring these products to market sooner.
Toward gender equity in contraceptive responsibility
Expanding male contraceptive options can promote fairness in reproductive health. By sharing contraceptive responsibility, couples can reduce unintended pregnancies and strengthen their relationships. The demand for male contraceptives reflects a broader cultural shift toward equality and shared decision-making.
This study highlights a critical moment for reproductive health innovation. With strong demand and promising developments, male contraceptives could soon reshape the landscape of family planning worldwide.
The Parsemus Foundation has a history of significant advocacy and financial support for non-hormonal male contraception, including support of the Clean Sheets pill, ultrasound, Gandarusa, and Vasalgel. The Parsemus Foundation supported the launch of the Male Contraceptive Initiative. Read our web page on male contraceptive research, and see our other blog posts on the topic.
